Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Calif. , March 26, 2015  Desert Valley ... Nation five times , is the first U.S. ... in its emergency department to help clinicians prevent hospital ... Victorville, Calif. , is a community ... bariatric patients.  Using the Leaf Patient Monitor in the ...
(Date:3/26/2015)... , March 26, 2015  The inaugural ... the use of health technology innovations that improve ... foster collaborations to improve development and adoption of ... the structures and processes within delivery systems that ... providers, investors, entrepreneurs, developers and other stakeholders, takes ...
(Date:3/26/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading ... healthcare industry in the United States ... secured a new $45.0 million credit facility with JPMorgan Chase ... facility with its prior lender group.  Effective ... senior secured credit agreement comprised of a $10.0 million asset-based ...
Breaking Medicine Technology:Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3HX360 To Highlight New, Innovative Technology-Based Solutions To Improve Care Coordination, Workflow, Patient Experience 2HX360 To Highlight New, Innovative Technology-Based Solutions To Improve Care Coordination, Workflow, Patient Experience 3HX360 To Highlight New, Innovative Technology-Based Solutions To Improve Care Coordination, Workflow, Patient Experience 4InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4
... -- Micell,Technologies announced today that the Company ... supercritical fluid (SCF) surface modification,technology for drug-eluting ... Annual Meeting, April 19-21 2007 in Chicago,Illinois. ... and PNNL's, 2006 R&D,100 Award winning e-RESS ...
... and CARLSBAD, Calif., April 18, 2007,/PRNewswire-FirstCall/ -- ... from a preclinical study in which BiTE(R) ... prevent,subcutaneous tumor growth and formation of lung ... is frequently,expressed on breast, colon and other ...
Cached Medicine Technology:Micell Technologies Presents Data on Novel Drug-Eluting Stents 2Micell Technologies Presents Data on Novel Drug-Eluting Stents 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 2Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 5
(Date:3/26/2015)... York (PRWEB) March 26, 2015 ... move forward nationwide, with the issuance of new ... Pennsylvania and Louisiana. According to an Order dated ... litigation established for Xarelto injury claims in the ... now allow plaintiffs to file cases directly in ...
(Date:3/26/2015)... March 26, 2015 “The SWEET Act is ... healthy options more available and help parents who are working ... is a reasonable approach to support public health, and we ... issue for the health of all families,” said Dr. Jane ... Health on the introduction of the Sugar-Sweetened Beverage Tax (SWEET) ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 Dr. ... are proud to announce expanded offerings for Bay Area ... Francisco Dental Implant Center has long been a top-rated ... expanded its offerings to meet the strong demand by ... our reputation as a top-rated dental implant facility in ...
(Date:3/26/2015)... Altamonte Springs, FL (PRWEB) March 26, 2015 ... one of the nation’s leading innovative specialty pharmacies, ... newly created position of Vice President of Pharmaceutical ... for fostering beneficial connections with our pharmaceuticals partners ... pharmaceutical relationships in support of BioPlus’ expansion. ...
(Date:3/26/2015)... London, UK (PRWEB) March 26, 2015 In ... 40 billion as of 2013 and is set to decrease ... billion by 2020; the growth is expected up to 2017 ... growth is expected to be owing to the surging penetration ... Tekturna HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... 81-year-old San Francisco woman with dementia, little money and an equally aged ... A 72-year-old Riverside woman with Alzheimer,s who cannot be left safely on ... care for her. A 78-year-old Los Angeles ... take care of him if day care services are cut. ...
... Angeles, London, New Delhi, Singapore and Washington DC (October ... with diabetes to modify their behavior, adjust their medicine ... to a recent study, published by SAGE in ... testing," a self-monitored testing both before and after specific ...
... remains a mystery, , THURSDAY, Oct. 1 (HealthDay News) -- ... still in their mother,s womb were about 20 percent more ... study has found. , The flu outbreak in 1918 killed ... the United States. That flu, like the current H1N1 swine ...
... ... to maximize cell culture media performance and will be on display at BioProcess International ... in Raleigh, North Carolina. , ... Fort Collins, CO (PRWEB) October 1, 2009 -- As conference exhibitor and ...
... The 2nd ... in New York, NY. This three-day conference will explore address all aspects of signal detection ... ... The 2nd DIA Conference on Signal Detection and Data Mining will be held ...
... Support for Addressing Crisis of Chronic Disease , ... are voicing their support for health reform that prioritizes ... to Health Reform" ( www.sayyestohealthreform.com ) - an ... (PFCD) directed at Congressional leaders in Washington. , The campaign ...
Cached Medicine News:Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 2Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 3Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 2Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 3Health News:InVitria's Better Ingredients for Better Media to be Showcased at BPI '09 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 3Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 2Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 3
... Conduit TCP is a synthetic porous ceramic ... similar to the mineral phase that comprises 70% ... that provides a scaffold that allows the attachment ... development of vascular networks within granules as well ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Weitlaner Beckmann retractor, sharp prongs, SS....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products: